Loading stock data…
Tyra Biosciences (TYRA)
$30.63-0.17 (-0.55%)
Market ClosedLast close Jul 24
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tyra Biosciences, Inc. in the Healthcare sector is trading at $30.63 with a market capitalization of $1.7B. Wall Street consensus targets $51.97 (12 analysts), implying a +69.7% move over the next 12 months. The stock is currently 25% below its 52-week high of $40.65, remaining 7.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +69.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.00M↓ | -$36.52M↓ | -$32.94M↓ | -$31.45M↑ | -$31.85M |
| Net Income | -$39.30M↓ | -$33.83M↓ | -$29.87M↓ | -$28.10M↑ | -$28.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.83%
Volume
Today's trading volume
627,486
Recent News
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list. TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target. The firm highlighted TYRA’s upcoming clinical […]
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?
Recently, analysts issued mixed commentary on Tyra Biosciences, balancing optimism around its FGFR3 inhibitor dabogratinib and a new board appointment with renewed questions about the SURF-302 program and broader macroeconomic pressures. This combination of confidence in one lead candidate and concern over another highlights how concentrated clinical pipelines can quickly reshape investor sentiment toward emerging biotechs. Against this backdrop, we’ll examine how reassurances around...
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says
Tyra Biosciences' (TYRA) weak investor sentiment reflects a mix of macro pressures, profit-taking, a
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target. The analyst stated dabogratinib could “achieve the CR bar for LR IR NMIBC” while remaining “on […]
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.